UNCY Stock Analysis: Buy, Sell, or Hold?
UNCY - Unicycive Therapeutics, Inc. Common Stock
$5.73
0.45 (8.52%)
▲
5d:
-30.21%
30d:
-20.75%
90d:
-19.52%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When UNCY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called UNCY this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: UNCY is down 30.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: UNCY is down 30.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$9.74
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$6.05
5.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: UNCY is currently trading at $5.73, which is considered oversold relative to its 30-day fair value range of $6.34 to $7.89. From a valuation perspective, the stock is trading at a discount (Forward PE: 0.9) compared to its historical average (1.1). Remarkably, the market is currently pricing in an annual earnings decline of 5.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, UNCY is in a uptrend. The price is currently testing key support at $6.65. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 8.5% recently.
Market Sentiment: UNCY has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $40.66 (+609.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, UNCY is in a uptrend. The price is currently testing key support at $6.65. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 8.5% recently.
Market Sentiment: UNCY has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $40.66 (+609.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.34 -
$7.89
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.5%)
- BULLISH: Trading 609.5% below Wall St target ($40.66)
- WARNING: Recommendation downgraded due to -30.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$6.34 -
$7.89
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$6.65
Resistance Level
$8.02
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
0.91
Wall Street Target
$40.66
(+609.5%)
Valuation Discount vs History
-5.2% cheaper
PE vs Historical
0.9 vs 1.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.2%
(market-implied from PE analysis)
1-Year Target
$5.43
(-5%)
2-Year Target
$5.15
(-10%)
3-Year Target
$4.88
(-15%)
3-Yr Target (if PE normalizes)
(PE: 1→1)
$5.92
(+3%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 0.9 to 1.1
Stabilization Target:
$6.95
(+21.3%)
PE Expansion Potential:
+21.3%
Share & Embed Analysis
Last updated: July 05, 2026 8:09 AM ET
Data refreshes hourly during market hours. Next update: 9:09 AM
Data refreshes hourly during market hours. Next update: 9:09 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UNCY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
IMCR
Immunocore Holdings Ltd |
STRONG BUY
17 analysts |
$63 | 64 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
